Barclays Maintains Underweight on NOV, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst David Anderson maintains an Underweight rating on NOV (NYSE:NOV) but raises the price target from $17 to $20.
July 30, 2024 | 11:53 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Barclays analyst David Anderson maintains an Underweight rating on NOV but raises the price target from $17 to $20.
The Underweight rating suggests a bearish outlook, but the raised price target indicates some positive expectations. The mixed signals likely result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100